WO2001082872A3 - A medicinal aerosol formulation - Google Patents

A medicinal aerosol formulation Download PDF

Info

Publication number
WO2001082872A3
WO2001082872A3 PCT/US2001/000032 US0100032W WO0182872A3 WO 2001082872 A3 WO2001082872 A3 WO 2001082872A3 US 0100032 W US0100032 W US 0100032W WO 0182872 A3 WO0182872 A3 WO 0182872A3
Authority
WO
WIPO (PCT)
Prior art keywords
aerosol formulation
medicinal aerosol
medicinal
relates
fluid carrier
Prior art date
Application number
PCT/US2001/000032
Other languages
French (fr)
Other versions
WO2001082872A2 (en
Inventor
Anthony J Cutie
Akwete L Adjei
Frederick A Sexton
Original Assignee
Aeropharm Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology Inc filed Critical Aeropharm Technology Inc
Priority to AU2001226233A priority Critical patent/AU2001226233A1/en
Publication of WO2001082872A2 publication Critical patent/WO2001082872A2/en
Publication of WO2001082872A3 publication Critical patent/WO2001082872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a rosiglitazone maleate and a fluid carrier.
PCT/US2001/000032 2000-05-01 2001-01-02 A medicinal aerosol formulation WO2001082872A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001226233A AU2001226233A1 (en) 2000-05-01 2001-01-02 A medicinal aerosol formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20105800P 2000-05-01 2000-05-01
US60/201,058 2000-05-01
US09/703,068 US6447750B1 (en) 2000-05-01 2000-10-31 Medicinal aerosol formulation
US09/703,068 2000-10-31

Publications (2)

Publication Number Publication Date
WO2001082872A2 WO2001082872A2 (en) 2001-11-08
WO2001082872A3 true WO2001082872A3 (en) 2002-01-24

Family

ID=26896351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000032 WO2001082872A2 (en) 2000-05-01 2001-01-02 A medicinal aerosol formulation

Country Status (3)

Country Link
US (2) US6447750B1 (en)
AU (1) AU2001226233A1 (en)
WO (1) WO2001082872A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
KR20030094377A (en) * 2001-05-04 2003-12-11 화이자 프로덕츠 인코포레이티드 Method of preventing type 2 diabetes with aerosolized insulin
JP2006509716A (en) * 2002-03-12 2006-03-23 マイクロドース・テクノロジーズ・インコーポレーテッド A method for delivering drugs coadministered by inhalation to a specific site
JP4681231B2 (en) 2002-03-20 2011-05-11 マンカインド コーポレイション Inhaler
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
BRPI0514263B8 (en) 2004-08-20 2021-05-25 Mannkind Corp method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7967873B1 (en) 2006-03-29 2011-06-28 Bozzetto, Inc. Dyed textile article and dye bath assistant
WO2009055740A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
CA2982550C (en) 2008-06-13 2020-08-25 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN102065942B (en) 2008-06-20 2013-12-11 曼金德公司 An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
WO2010065843A2 (en) 2008-12-05 2010-06-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biologic scaffold for prevention of pulmonary fibrosis
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
ES2943333T3 (en) 2009-06-12 2023-06-12 Mannkind Corp Diketopiperazine microparticles with defined surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CN107051718A (en) * 2011-03-11 2017-08-18 杨贵生 Magnetic-particle remove device and method
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
CN103826988B (en) 2011-04-01 2016-03-09 曼金德公司 For the blister package of pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (en) 2011-10-24 2016-11-02 マンカインド コーポレイション Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102391750B1 (en) 2013-03-15 2022-04-28 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
CN105451716A (en) 2013-07-18 2016-03-30 曼金德公司 Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (en) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
EP0748213B1 (en) * 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] EVANS ET AL.: "Recent developments and emerging therapies for type 2 diabetes mellitus", XP002947961, accession no. STN Database accession no. 2000:194936 *
DRUGS R&D, vol. 2, no. 2, 1999, pages 75 - 94 *

Also Published As

Publication number Publication date
WO2001082872A2 (en) 2001-11-08
US6447750B1 (en) 2002-09-10
AU2001226233A1 (en) 2001-11-12
US6645468B2 (en) 2003-11-11
US20030012739A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2001082872A3 (en) A medicinal aerosol formulation
AU2471601A (en) A medicinal aerosol formulation
AU2001271790A1 (en) Child-resistant product package
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
AU2002216217A1 (en) Semiconductor package
ZA200206728B (en) Cosmetic compositions containing a methacrylic acid copolymer and an oil, and uses thereof.
AU8649401A (en) A practical, cost-effective synthesis of coq10
WO2001082874A3 (en) A medicinal aerosol formulation
AU2001234114A1 (en) Drugs containing combined active ingredients
WO2002040016A8 (en) Association of calpain inhibitors and reactive oxygen species trapping agents
HK1050610A1 (en) Microemulsion aerosol composition.
WO2001082873A3 (en) A medicinal aerosol formulation
AU2908700A (en) Package for a fluid cosmetic composition
ZA200100565B (en) Benzenesulfonamide compounds, a process for their preparation and pharmaceutical compositions containing them.
ZA200110517B (en) Metalloprotease inhibitors, a process for their preparation and pharmaceutical compositions containing them.
ZA200304928B (en) Medicament containing a polyamine as an active substance.
ZA200107909B (en) Stable aqueous compositions containing a silicon compound.
ZA200303113B (en) Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them.
AU2001259318A1 (en) A medicinal aerosol formulation
AU2001252418A1 (en) Nasal packing device
AU2001274171A1 (en) Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
AU2001245873A1 (en) Wireless, intrinsically safe valve
HK1047101A1 (en) Bicyclic amino-pyrazinone compounds, a process fortheir preparation and pharmaceutical compositions containing them.
AU2002304138A1 (en) Capped aerosol container
AU2001240611A1 (en) Packaging for a plaster containing active ingredients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP